Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2009, Article ID 596560, 8 pages
Research Article

In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography

1Section of Pediatric Hematology & Oncology, Herman B Wells Center for Pediatric Research, Indiana University Simon Cancer Center, 1044 West Walnut Street R4 321, Indianapolis, IN 46202, USA
2Therapeutic Area Oncology, Lilly Research Laboratories, Indianapolis, IN 46285, USA
3Program Phase Statistics, Lilly Research Laboratories, Indianapolis, IN 46285, USA
4Oncology Discovery, Lilly Research Laboratories, Indianapolis, IN 46285, USA
5Department of Radiology, Indiana University Cancer Center, Indianapolis, IN 46202, USA

Received 21 July 2008; Accepted 13 March 2009

Academic Editor: Bruce Baguley

Copyright © 2009 Karen E. Pollok et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. The use of 2-[ 1 8 F ]fluoro-2-deoxy-D-glucose ([ 1 8 F ]FDG) may help to establish the antitumor activity of enzastaurin, a novel protein kinase C-beta II (PKC- 𝛽 II) inhibitor, in mouse xenografts. Methods. The hematologic cell line RAJI and the solid tumor cell line U87MG were each implanted in NOD/SCID mice. Standard tumor growth measurements and [ 1 8 F ]FDG PET imaging were performed weekly for up to three weeks after tumor implantation and growth. Results. Concomitant with caliper measurements, [ 1 8 F ]FDG PET imaging was performed to monitor glucose metabolism. Heterogeneity of glucose uptake in various areas of the tumors was observed after vehicle or enzastaurin treatment. This heterogeneity may limit the use of [ 1 8 F ]FDG PET imaging to measure enzastaurin-associated changes in xenograft tumors. Conclusion. [ 1 8 F ]FDG PET imaging technique does not correlate with standard caliper assessments in xenografts to assess the antitumor activity of enzastaurin. Future studies are needed to determine the use of [ 1 8 F ]FDG PET imaging in preclinical models.